6190 PhoenixBio
- 515
- +16+3.21%
PhoenixBio News
PXI Research Memo (10): After achieving the elimination of accumulated losses and establishing a stable financial structure, the policy of shareholder returns will be implemented.
Regarding shareholder returns, we have recorded cumulative losses since our founding. Currently, we are in a stage of establishing our business through research and development and capital investment, therefore we have not implemented profit dividends.
PXG Research Memo (9): Expanding product sales and more for the high-growth next-generation pharmaceutical market.
Phoenix Bio's growth strategy 2. Against the backdrop of expanding markets for next-generation pharmaceuticals, including growth nucleic acid pharmaceuticals, and expanding demand for liver cells, the company has set a growth strategy to expand sales of its products (PXB mouse, PXB-cells related products) and outsourcing safety testing services in the high-growth next-generation pharmaceuticals market. Regarding PXB mouse, the company plans to expand sales channels and production facilities in Japan and North America in response to increased demand.
PX Research Memo (8): The market environment is favorable.
Phoenix Bio's growth strategy: 1. Market environment Pharmaceutical development is shifting to the next-generation pharmaceuticals (nucleic acid drugs, cell therapy/regenerative medicine, etc.), which are more effective and safer, targeting not only low-molecular-weight drugs and antibody drugs targeting "proteins" that cause diseases, but also the synthesis of "proteins" that cause diseases by targeting human "DNA" and "RNA". This trend is based on drug discovery modalities (drug development
Financial estimates show significant growth in revenue and profit for the March 2025 fiscal year in PXB's Research Memo (7).
Future Outlook: Overview of Financial Estimates for FY 2025 Phoenixbio <6190>'s consolidated revenue for the fiscal year ended March 2025 is expected to increase significantly, with revenues of 2,121 million yen, up 23.7% from the previous year, operating profit of 214 million yen (11 million yen in the previous year), ordinary profit of 214 million yen, up 393.6% from the previous year, and net income attributable to shareholders of the parent company of 201 million yen, up 662.3% from the previous year, all attributed to the significant gains from new drug development using new modalities such as nucleic acid pharmaceuticals and gene therapy.
PXB Research Memo (5): Pharmaceutical companies' investment in new drug development is a risk factor.
Overview of Phoenix Bio <6190> Business 4. Risk factors and challenges/countermeasures Risk factors include trends in investment in new drug development by pharmaceutical companies and research institutions, trends in competition, and legal regulations. With regard to trends in investment in new drug development by pharmaceutical companies and research institutions, the discontinuation of the development of anti-hepatitis B virus drugs by overseas pharmaceutical companies has resulted in a significant decline in revenue from contract testing services, and the risk has become apparent. In response to this, the company is engaged in activities related to anti-hepatitis B virus drugs.
PXG Research Memo (4): Shift in strategy toward product sales, orders are bottoming out in the March 2023 period and on a recovery trend.
Phoenix Bio's business overview: 3. Revenue by field and service line In the 2024 fiscal year ending in March, revenue from the pharmacology and pharmacology field was 159 million yen, while revenue from the safety and other areas was 1,556 million yen. Revenue by service line was 1,320 million yen from product sales and 396 million yen from contract testing services. The number of customers in the safety and other areas decreased by 3 companies compared to the previous period to 38 companies overseas and by 7 companies to 59 companies domestically. In the fiscal year ending in March 2024, Alnylam was the main sales destination.
PXB Research Memo (3): Launching Sales and Contract Testing Services for Fresh Human Liver Cell-Related Products
- Business Overview Phoenix Bio's drug discovery support services include the sales of the company's unique high-quality human liver chimeric mouse, PXB mouse, sales of related products such as fresh human liver cells (PXB-cells) collected from PXB mice, and contracted testing services for drug evaluation (efficacy evaluation, safety evaluation, etc.). The company conducts contracted testing services through its own contracted testing department as well as utilizing external CROs (contracted testing implementation agencies) with which it has business partnerships.
PXV Research Memo (2): The management philosophy is to contribute to the promotion of people's health through the scientific study of life.
Company Overview: Phoenix Bio Co., Ltd. (<6190>) has a management philosophy of "contributing to the improvement of people's health by studying life scientifically" and provides support for drug discovery to pharmaceutical companies and research institutions around the world. As of the end of March 2024 (consolidated basis), the total assets were JPY 2,715 million, the net assets were JPY 1,797 million, and the self-capital ratio was 65.7%. The headquarters is located in Kagamiyama, Higashihiroshima City, Hiroshima Prefecture, and the group consists of the company and its consolidated subsidiaries.
Phoenix Bio --- 1Q revenue increased, contributed by the weak yen.
Phoenix Bio <6190> announced its consolidated financial results for the first quarter of the 2025 fiscal year (April-June 24) on the 13th. The revenue was 0.449 billion yen, a 2.3% increase from the same period of the previous year. Operating profit was 0.005 billion yen, a 16.9% decrease. Ordinary profit was 0.025 billion yen, a 47.1% decrease. The quarterly net profit attributable to the parent company's shareholders was 2.3 billion yen, a 45.0% decrease. The demand for PXB mice is shifting from the hepatitis field to the biopharmaceutical field, and it is being used in the development of nucleic acid pharmaceuticals and gene therapy, etc.
PhoenixBio: Short message of first quarter financial results for the fiscal year of March 2025 [Japan Standard] (Consolidated)
PhoenixBio 1Q Net Y23.00M Vs Net Y42.00M
PhoenixBio Sees 1H Loss Y8.00M
Volume change rate ranking (13:00)~Naigai, Sanbio, etc. are ranked.
* In the volume change rate ranking, by comparing the average volume of the past 5 days with the volume on the distribution day, you can understand the interest of market participants such as trends in selection. * Top volume change rate [as of July 29, 13:51] (comparison with the average volume of the past 5 days) Code ⇒ Brand ⇒ Volume ⇒ Average volume for 5 days ⇒ Volume change ratio ⇒ Stock price change ratio <7162> Astramax 2974900 12425.46 370.30% 0.1603% <3195> Ji
Volume change rate ranking (9:00 am) - Libomic, Yumiru link and other companies are ranked in.
*In volume change rate rankings, you can understand the interest of market participants, such as trending stocks, by comparing the volume for the most recent 5 days with the volume on the day of release. *Volume Change Rate Ranking Top [as of 9:32 on July 19] (Comparison with the most recent 5-day average volume): Stock Code and Name Volume 5-day Average Volume Volume Change Rate Stock Price Change Rate ＜7446＞ Tohoku Chemical 200 107185.08 400% 0% ＜3409＞ Kita-Nippon Bank
PhoenixBio: Extraordinary Report
PhoenixBio: Confirmatory letter.
PhoenixBio: Financial Report - Term 23 (2023/04/01 - 2024/03/31)
Stocks with interesting flavors seen from changes in volume, such as REMIX.
Code Closing price Change Volume ＜3848＞Data application 1000 98 199300 ＜4937＞Waqoo 1795 27 63500 ＜6190＞PXB 513 25 63300 ＜5035＞Housei 499 21 188400 ＜2525＞NZAM 225 40460 520 5131
Check out the disclosed information for [Tomorrow's Good and Bad Materials]! (Announced on 5/15)
[Good news] ---- ---- ■ITbook Holdings [Tokyo Stock Exchange G] Current financial results increased 26% to the highest profit for 4 consecutive terms, to 6 yen this fiscal year. ■GNI Group [TSE G] landed in surplus at the end of the January-March period (1Q). Also, we will proceed with preparations for applying for a market classification change to the Tokyo Stock Exchange Prime Market. In addition, a joint venture for drug discovery and investment businesses utilizing AI technology will be established with Oltz and Governance Partners. ■Huh
PHOENIXBIO: Notice regarding financial results of unlisted parent companies, etc.
Analysis
Price Target
No Data
